Megan Tesch, MD, Dana Farber Cancer Institute, Boston, MA, discusses immune infiltration patterns in breast tumors of women aged under 40 undergoing neoadjuvant chemotherapy and their correlation with treatment outcomes. Tumor-infiltrating lymphocytes (TILs) vary by recent pregnancy, BRCA1 mutation status, and tumor characteristics, with higher TIL levels predicting better pathologic complete response (pCR). This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
